Litigation

Humana Inc. v. Celgene Corp.

partially dismissed; amended complaints filed

2:19-cv-07532

Auto-generating section 1 of 5: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Patents at issue (1)

Plaintiffs (1)

Defendants (1)

Summary

Antitrust follow-on litigation where purchasers/insurers allege Celgene used the '740 and related method-of-treatment patents, serial sham suits, and reverse-payment settlements to delay generic lenalidomide. The court dismissed the insurer and MSP operative complaints on June 6, 2024, with later amended complaints filed.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).